Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for PROCEPT BioRobotics (PRCT) over the last 6 years, with Q3 2025 value amounting to $21.8 million.

  • PROCEPT BioRobotics' Accumulated Expenses rose 1573.22% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 1573.22%. This contributed to the annual value of $21.5 million for FY2024, which is 2755.11% up from last year.
  • PROCEPT BioRobotics' Accumulated Expenses amounted to $21.8 million in Q3 2025, which was up 1573.22% from $16.3 million recorded in Q2 2025.
  • In the past 5 years, PROCEPT BioRobotics' Accumulated Expenses registered a high of $21.8 million during Q3 2025, and its lowest value of $4.6 million during Q1 2022.
  • For the 5-year period, PROCEPT BioRobotics' Accumulated Expenses averaged around $12.6 million, with its median value being $13.3 million (2023).
  • As far as peak fluctuations go, PROCEPT BioRobotics' Accumulated Expenses surged by 11095.38% in 2022, and later soared by 954.17% in 2025.
  • PROCEPT BioRobotics' Accumulated Expenses (Quarter) stood at $6.5 million in 2021, then soared by 107.68% to $13.4 million in 2022, then grew by 25.57% to $16.9 million in 2023, then increased by 27.55% to $21.5 million in 2024, then increased by 1.21% to $21.8 million in 2025.
  • Its last three reported values are $21.8 million in Q3 2025, $16.3 million for Q2 2025, and $15.0 million during Q1 2025.